Promacta Articles
FDA backs new indication for GlaxoSmithKline's Promacta
20 November 2012
GlaxoSmithKline files for new eltrombopag indications in EU and USA; gains rights to derma products
31 May 2012
US FDA clears Takeda’s Edarbi for hypertension and grants full approval for GSK’s Promacta
28 February 2011
Disappointments for NicOx, as FDA panel rejects naproxcinod, and GlaxoSmithKline, which halts Promacta trial
13 May 2010
Europe’s CHMP serves up negative opinion for Ark’s Cerepro and calls for ban on benfluorex drugs, but good news for B-MS, Sanofi, GSK, Novartis
21 December 2009
Ligand narrows loss on rocketing revenue
8 May 2009
Ligand gets $500K under GSK accord
31 March 2009
Ligand swings to loss on merger and legal fees
23 February 2009
FDA 2008 NCE appros exceed expectations
12 January 2009
Ligand licenses drug to GSK for $163M
12 January 2009
ASH hears strong data on Novartis
22 December 2008
Stock Commentary - New York week to Dec 8, 2008
15 December 2008
Positive Ph III data for GSK ITP drug
15 December 2008
Stock Commentary - Europe - week to Nov 24, 2008
1 December 2008
FDA approves GSK and Ligand's Promacta
1 December 2008
Stock Commentary - New York week to Nov 24, 2008
1 December 2008
FDA delays NDA reviews despite budget rise
3 November 2008
Stock Commentary - New York week to Oct 27, 2008
3 November 2008
Ligand reports second quarter in loss
1 September 2008
Stock Commentary - New York week to July 14, 2008
21 July 2008
3 month delay for approval of Ligand/GSK's Promacta
14 July 2008
Promacta gets nod from US FDA panel
9 June 2008
Ligand falls into loss in 1st qtr
19 May 2008
GSK/Ligand's Promacta to get FDA priority review
10 March 2008
Ligand reports 4th-qtr 2007 income of $5.8M
3 March 2008
Promacta raises platelet counts in HCV and ITP
17 December 2007
Stock Commentary - New York week to Dec 3, 2007
10 December 2007
GSK's Promacta raises platelet levels
10 December 2007
GSK initiates Ph III hep C Promacta studies
21 November 2007
GSK starts REPEAT dosing of Promacta
23 April 2007
GSK reports strong Ph II data on Promacta: first ever oral drug for treatment of ITP
18 December 2006
GSK initiates Ph III trial of Promacta
11 December 2006
Ligand sells oncology line to Eisai and Avinza to King for total $518M
18 September 2006
Showing 1-37 of 37 articles
- 1
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
